DMK Pharmaceuticals Corp Watch

from 10-Q 19 pages Adamis Pharmaceuticals Corporation and Equiniti Trust Company, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August 4, 2023 Warrant Agency Agreement

from 10-Q 15 pages Common Stock Purchase Warrant Adamis Pharmaceuticals Corporation

from S-1 31 pages Securities Purchase Agreement

from S-1 18 pages Adamis Pharmaceuticals Corporation and Equiniti Trust Company, LLC, as Warrant Agent Warrant Agency Agreement Dated as of July __, 2023 Warrant Agency Agreement

from S-1 14 pages Pre-Funded Common Stock Purchase Warrant Adamis Pharmaceuticals Corporation

from S-1 15 pages Common Stock Purchase Warrant Adamis Pharmaceuticals Corporation

from 10-Q 27 pages Adamis Pharmaceuticals Corporation Prefunded Warrant to Purchase Common Stock

from 10-Q 26 pages Adamis Pharmaceuticals Corporation Warrant to Purchase Common Stock

from 8-K 26 pages Form of Prefunded Warrant

from 8-K 26 pages Form of Warrant

from S-3 39 pages Adamis Pharmaceuticals Corporation Indenture Dated as of , 20___ [ ] Trustee

from DEFA14A 20 pages Common Stock Purchase Warrant Adamis Pharmaceuticals Corporation

from 8-K 20 pages Common Stock Purchase Warrant Adamis Pharmaceuticals Corporation

from 10-K 8 pages Description of Capital Stock

from 8-K 6 pages Description of Capital Stock

from 10-K 5 pages Description of Capital Stock

from 8-K 20 pages Common Stock Purchase Warrant Adamis Pharmaceuticals Corporation

from 10-Q 17 pages Adamis Pharmaceuticals Corporation Warrant to Purchase Common Stock

from 8-K 22 pages Adamis Pharmaceuticals Corporation, a Company Organized Under the Laws of Delaware (The “Company”), Hereby Certifies That, for Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, [Holder], the Registered Holder Hereof or Its Permitted Assigns (The “Holder”), Is Entitled, Subject to the Terms Set Forth Below, to Purchase From the Company, at the Exercise Price (As Defined in Section 1(b) Below) Then in Effect, at Any Time or Times on or After the Issuance Date (The “Exercisability Date”), but Not After 11:59 P.M., New York Time, on the Expiration Date, (As Defined in Section 16 Below), ( )1 Fully Paid Non-Assessable Shares of Common Stock (As Defined in Section 16 Below), Subject to Adjustment as Provided Herein (The “Warrant Shares”). Except as Otherwise Defined Herein, Capitalized Terms in This Warrant to Purchase Common Stock (Including Any Warrants to Purchase Common Stock Issued in Exchange, Transfer or Replacement Hereof, This “Warrant”), Shall Have the Meanings Set Forth in Section 16. This Warrant Is One of the Warrants to Purchase Common Stock (The “Warrants”) Issued Pursuant to (I) That Certain Underwriting Agreement, Dated as of [ ], 2019 (The “Subscription Date”) by and Between the Company and Raymond James & Associates, Inc., (II) the Company’s Registration Statement on Form S-3 (File Number 333-226100) (The “Registration Statement”), and (III) the Company’s Prospectus Supplement Dated as of [ ], 2019. 1 Insert [ ]% of the Number of Shares of Common Stock Purchased Pursuant to the Underwriting Agreement. 1. Exercise of Warrant

from S-8 20 pages Adamis Pharmaceuticals Corporation 2009 Equity Incentive Plan